1. Introduction {#sec1-ijerph-17-01035}
===============

Type 2 diabetes (T2D) is a global health burden that affects hundreds of millions of people \[[@B1-ijerph-17-01035]\]. It is characterized by glucose dyshomeostasis, hyperglycaemia and insulin resistance, with predisposing factors that include obesity, poor quality diet, insufficient physical activity and genetic factors \[[@B2-ijerph-17-01035],[@B3-ijerph-17-01035]\]. These factors interact to cause failure of circulating glucose level regulation which can result in an inability to supply sufficient insulin and eventual beta-cell loss that exacerbates the condition \[[@B4-ijerph-17-01035],[@B5-ijerph-17-01035]\]. Glucotoxicity caused by chronic hyperglycemia induces cell injury of many cell types but hepatocytes and pancreatic cells in particular \[[@B6-ijerph-17-01035]\]. Hyperglycaemia classically causes vascular disease, damaging blood vessels and leading to a range of cardiovascular diseases. In addition, hyperglycemia has a number of long term effects that exacerbate impairments of central nervous system (CNS) function and cognitive function \[[@B7-ijerph-17-01035]\]. Metabolic changes seen in T2D patients lead to chronic CNS inflammation that contribute to neurodegeneration \[[@B8-ijerph-17-01035]\]. Other T2D associated metabolic disturbances are associated with atrophy in several regions of the brain (e.g., hippocampal) that in turn are associated with cognitive impairment \[[@B9-ijerph-17-01035]\]. The brain is a very insulin-sensitive organ, so insulin resistance itself can affect memory and learning \[[@B10-ijerph-17-01035]\]. Indeed, glucose levels affect neuronal maintenance, neurogenesis, neurotransmitter regulation, cell survival and synaptic plasticity \[[@B11-ijerph-17-01035]\]. Moreover, it is notable that neurodegenerative diseases are accompanied by high production of inflammatory mediators, oxidative stress, Deoxyribonuclic acid (DNA) damage, and mitochondrial dysfunction which in turn also contribute to the degenerative cascade and exacerbate insulin resistance \[[@B12-ijerph-17-01035]\]. T2D is also associated with excessive immune system activation \[[@B13-ijerph-17-01035]\].

While the detailed mechanisms remains unclear, epidemiological, cognitive, and neuropathological evidence shows associations between T2D and neurodegenerative diseases such as Alzheimer's disease (AD) \[[@B14-ijerph-17-01035]\], amyotrophic lateral sclerosis (ALS) \[[@B15-ijerph-17-01035]\], cerebral palsy (CP) \[[@B16-ijerph-17-01035]\], epilepsy disease (ED) \[[@B17-ijerph-17-01035]\], Huntington's disease (HD) \[[@B18-ijerph-17-01035]\], multiple sclerosis (MS) \[[@B19-ijerph-17-01035]\], and Parkinson's disease (PD) \[[@B20-ijerph-17-01035]\]. Interestingly, neuroimaging studies of the CNS of individuals with T2D also show structural alterations that resemble those in neurological disease patients \[[@B21-ijerph-17-01035]\]. The high incidence of T2D thus raises issues around its interaction with other diseases occurring in the same individuals.

Epidemiological studies show a particularly strong association between T2D and AD \[[@B14-ijerph-17-01035]\]. AD is characterized by the accumulation of $\beta$-amyloid (A$\beta$) into neuritic plaques and the presence of intracellular aggregates of tau protein in neurofibrillary tangles, amylin deposition as well as synaptic loss, neuroinflammation, and neuronal death \[[@B14-ijerph-17-01035]\]. Although its etiology still remains unclear, genetic predisposition and aging are strong risk factors for AD \[[@B22-ijerph-17-01035]\]. Moreover, the presence of (A$\beta$) and tau in the pancreas and insulin-sensitive tissues and their roles in inducing peripheral insulin resistance or disruptions in insulin secretion indicate that this may contribute to the incidence of AD \[[@B14-ijerph-17-01035]\].

A wealth of evidence indicates a link between T2D and ALS \[[@B15-ijerph-17-01035]\]. ALS is a disorder characterized by progressive muscular atrophy, cognitive impairment, and pyramidal deficit, due to the degeneration of upper and lower motor neurons \[[@B23-ijerph-17-01035]\]. Motor neuron loss is associated with mutations in the Cu/Zn superoxide dismutase (SOD1) gene in this disease. ALS patients have altered lipid and glucose metabolism with increased energy consumption \[[@B24-ijerph-17-01035]\] and hypermetabolism \[[@B25-ijerph-17-01035]\]. Nevertheless, the biological mechanisms linking T2D to ALS are yet unclear even though there are clearly important risk factors in common, including environmental factors, higher body mass index (BMI), elevated cholesterol level and hyperlipidemia \[[@B26-ijerph-17-01035]\].

T2D also shows associations with CP, a neurodevelopmental disorder characterized by permanent movement-related disabilities, evident in early life, due to abnormalities in the brain centres that control movement and balance \[[@B16-ijerph-17-01035]\]. There are developmental issues in the fetus that lead to CP may have a link to maternal T2D incidence \[[@B27-ijerph-17-01035]\], and as maternal obesity and T2D might raise the risk of CP occurring \[[@B16-ijerph-17-01035]\]. Notably, children with CP may develop T2D as an adult. The etiology of CP is unclear but the role of perinatal factors such as chorioamnionitis hypoxic-ischemic encephalopathy as well as brain injury occurring during the perinatal and postnatal periods may contribute to CP \[[@B28-ijerph-17-01035]\].

T2D is also linked to ED \[[@B17-ijerph-17-01035]\]. This is a group of neurological diseases characterized by epileptic seizures. The precise relationship between T2D and epilepsy remains unclear. It is known that epilepsy or seizures are associated with autoimmune or inflammatory disorders and in the pro-inflammatory processes \[[@B29-ijerph-17-01035]\]. Additionally, hyperglycemia may exert adverse effects on the central nervous system which leads to ED \[[@B30-ijerph-17-01035]\]. Some known risk factors including degenerative brain disorders and head injuries, stroke and dementia are considered as predisposing factors to ED \[[@B31-ijerph-17-01035]\].

HD is a neurodegenerative disorder caused by an expanded CAG repeat in exon 1 of the huntingtin gene (HTT) encoding huntingtin protein and characterized by progressive disturbances of mood and motor function, and by cognitive dysfunction \[[@B32-ijerph-17-01035]\]. The pathogenetic mechanisms behind HD include misfolding and aggregation of the huntingtin protein, oxidative stress, impaired mitochondrial metabolism, excitotoxicity in affected brain regions, and impairment of the ubiquitin-proteasome system \[[@B32-ijerph-17-01035]\]. Although Huntington's disease (HD) is primarily considered a rare neurodegenerative disorder, insulin resistance and impaired glucose metabolism contribute to its development \[[@B33-ijerph-17-01035]\].

MS is a chronic inflammatory and progressive immune-mediated disease of the central nervous system (CNS), characterized by a selective and coordinated inflammatory destruction of the myelin sheath, with damage to the axon \[[@B34-ijerph-17-01035]\]. Inflammation, demyelination, and axonal degeneration are associated with MS. Moreover, insulin resistance may induce inflammatory responses, oxidative stress and could exacerbate cognitive impairments in individuals with MS \[[@B19-ijerph-17-01035]\]. Though the links between T2D and risk of MS incidence is unclear, there are common genetic and environmental factors that contribute to the MS \[[@B34-ijerph-17-01035]\].

PD is clinically characterized by severe motor symptoms that include postural instability, resting tremor, muscular rigidity, and slowness of movements and pathologically characterized by the preferential loss of dopaminergic neurons \[[@B20-ijerph-17-01035]\]. PD features the presence of intracellular inclusions, known as Lewy bodies, rich in fibrillar $\alpha$-Synuclein (aS), a protein suggested being involved in synaptic vesicle recycling and docking \[[@B35-ijerph-17-01035]\]. Several epidemiological studies have demonstrated that PD patients have impaired insulin signaling and insulin resistance, and hyperglycaemia which play a role to suppress dopaminergic neuronal activity and that decreasing dopamine turnover that contributes to the possible progression of PD \[[@B36-ijerph-17-01035]\].

In sum, there is good evidence that there are pathologically and clinically significant relationships between T2D and many NDs but the association has not been widely examined. As the etiology of T2D and NDs are quite complex and their risk factors somewhat tend to overlap, their biological basis and the molecular mechanisms that underlie this link are still not well understood. Finding interactions between T2D and NDs is very difficult, but is of great interest in medical endocrinology. T2D and NDs are very complex diseases in terms of their clinical presentations, and because of this they are hard to study by conventional hypothesis-driven endocrinology research, despite the high clinical importance. Moreover, there is still a lack of bioinformatics studies addressing the relationship between T2D and NDs. The aim of this study was to identify such links between T2D and NDs, since understanding the nature of these links could bring important insights into the mechanisms that underlie these diseases. This led us to employ a bioinformatics system pipeline, to analyze gene expression data from studies of disease-affected tissues for clues to the nature of the relationship between T2D and NDs.

Here, we focus on finding ND-associated differentially expressed genes (DEGs), molecular pathways and putative discriminative biomarkers that are common to both T2D and NDs. We subsequently performed the validation of the results with gold benchmark experimentally validated databases that include dbGaP, OMIM and OMIM Expanded, and literature.

2. Materials and Methods {#sec2-ijerph-17-01035}
========================

2.1. Datasets Employed in This Study {#sec2dot1-ijerph-17-01035}
------------------------------------

We query datasets from the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) \[[@B37-ijerph-17-01035]\]. Queries for each disease returns a number of datasets but most of them were discarded for having a sample size below our selected cutoff sample size of at least 7, having no two conditions such as control vs case or control vs treated, replicate datasets, having undesirable formatting or irrelevant experimental focus, RNAseq datasets, and datasets from non-human organisms. Here, we used datasets by seeking those that would minimise any bias and noise for this type of analysis. This process identified 8 datasets that are highly relevant to T2D, AD, ALS, CP, ED, HD, MS, and PD are appropriate for our study.

We analyzed different human gene expression datasets with accession numbers GSE23343 \[[@B38-ijerph-17-01035]\], GSE28146 \[[@B39-ijerph-17-01035]\], GSE833 \[[@B40-ijerph-17-01035]\], GSE31243 \[[@B41-ijerph-17-01035]\], GSE22779 \[[@B42-ijerph-17-01035]\], GSE1751 \[[@B43-ijerph-17-01035]\], GSE38010 \[[@B44-ijerph-17-01035]\]. and GSE19587 \[[@B45-ijerph-17-01035]\], having control and disease affected individuals for our study. The T2D dataset (GSE23343) contained gene expression data obtained from liver biopsies of 10 T2D hyperglycemic patients and 7 normoglycemic controls using an Affymetrix Human Genome U133 Plus 2.0 arrays. The AD dataset (GSE28146) was microarray data (also Affymetrix U133 Plus 2.0 arrays) on RNA from snap-frozen brain tissue where white matter tissue was extracted by laser capture methods to collect only CA1 hippocampal gray matter. The ALS dataset (GSE833) employing Affymetrix HuGeneFL Hu6800 arrays, was a study of postmortem spinal cord gray matter samples from 7 ALS patients and from 4 control. The CP (GSE31243) dataset was generated from 40 Affymetrix human genome U133A 2.0 microarray studies of hamstring muscle samples from 20 controls (taken during tissue reconstruction) and 20 CP patients. The ED dataset (GSE22779) was a gene expression profile of peripheral blood mononuclear cells from 12 healthy control and individuals 4 with epilepsy in a study of in vivo glucocorticoid treatment; only data from blood cells extracted before glucocorticoid treatment were used. The HD dataset (GSE1751) was taken from peripheral blood cells from 14 healthy control and 12 symptomatic HD-affected individuals along with 5 presymptomatic HD patients; this also used U133A arrays. The MS dataset (GSE38010) using U133A array data from 5 MS patient brain lesions (identified histologically) compared with 2 brain tissue samples from control individuals. The PD dataset (GSE19587) was an analysis taken from affected brain areas of 12 postmortem brains of PD patients and 10 control samples of unaffected brain tissue using Affymetrix U133A Plus 2.0 arrays.

2.2. Preprocessing and Identification of Differentially Expressed Genes {#sec2dot2-ijerph-17-01035}
-----------------------------------------------------------------------

We acquired gene expression microarray datasets from the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO). All these datasets were generated by comparing diseased tissue against controls to identify differentially expressed genes (DEGs) associated with their respective pathology. To make uniform the mRNA expression data from different platforms and to avoid the problems of experimental systems, we normalized the gene expression data comprising disease state and control data by using the Z-score transformation ($Z_{ij}$) for each NDs gene expression profile using the following equation:$$Z_{ij} = \frac{g_{ij} - \overline{X}}{\sigma_{i}}$$ where $\sigma_{i}$ implies standard deviation and $g_{ij}$ indicates gene expression magnitude *i* in sample *j*. Such a transformation allows direct comparisons of gene expression values across samples and diseases. The datasets were normalized using the Robust Multi-Array Average expression measure (version 1.30.1) as implemented in the "affy" package (version 1.56.0) of the Bioconductor platform (version Rx64 3.3.0) in R. We performed the analysis of the microarray data using Linear Models for Microarray Data (Limma) \[[@B46-ijerph-17-01035]\]. Unpaired *t*-test statistic was used to identify genes differentially expressed in patients compared to normal samples. Moreover, to determine the statistical significance between groups, a two-way analysis of variance (ANOVA) with the false discovery rate (FDR) test was performed. Based on standard statistical criteria, a threshold of at least 1 log2 fold change (logFC) and *t*-tests giving a *p*-value of 0.01 were chosen. *p*-value \< 0.01 and logFC \> 1 for up-regulated genes and *p*-value \< 0.01 and logFC \< −1 for down-regulated genes were used. Genes with significantly different expression were thus selected. Gene symbols and names extracted for each disease. Gene symbol records with null or missing data were discarded for each disease. We identified both unique genes that were both over and under-expressed in NDs and T2D. We then pairwise compared the DEGs from T2D datasets with that of our AD, ALS, CP, ED, HD, MS, and PD datasets to find DEGs common to T2D and the NDs. Genes with the greatest magnitude up and down-regulation were selected from those common to the individual disease and T2D.

We then applied neighborhood benchmarking and topological methods to show the associations between genes and diseases. A gene-disease network in short GDN was built to identify gene-disease connections, in which nodes can be either diseases or genes; such a network is represented as a bipartite graph where T2D is the center of this network using Cytoscape V 3.6.1. \[[@B47-ijerph-17-01035]\]. Diseases are associated when sharing at least one significantly dysregulated gene. For gene-disease association, we consider a set of human diseases, denoted by D and a set of human genes, denoted by G to find whether gene $g \in G$ is associated with disease $d \in D$. Moreover, we consider that if $G_{i}$ and $G_{j}$ is the sets of genes with significantly up and down-regulated that were associated with diseases $D_{i}$ and $D_{j}$, respectively, then the number of shared dysregulated genes $\left( n_{ij}^{g} \right)$ associated with both disease $D_{i}$ and $D_{j}$ is defined as follows \[[@B48-ijerph-17-01035]\]:$$n_{ij}^{g} = N\left( G_{i} \cap G_{j} \right).$$

The co-occurrence is the number of common genes between two diseases in the GDN and common neighbors identified employing Jaccard Coefficient methods \[[@B48-ijerph-17-01035]\], where edge predictions score (association score) for the node pair is:$$E\left( i,j \right) = \frac{N\left( G_{i} \cap G_{j} \right)}{N\left( G_{i} \cap G_{j} \right)},$$ where *G* is the set of nodes and *E* is the set of edges. We also applied R software packages comoR \[[@B49-ijerph-17-01035]\], and POGO \[[@B50-ijerph-17-01035]\] to cross-check disease comorbidity associations.

2.3. Identification of Molecular Pathway and Gene Ontology {#sec2dot3-ijerph-17-01035}
----------------------------------------------------------

To obtain further insights into the molecular pathways and gene ontology (GO) of T2D that overlap with AD, ALS, CP, ED, HD, MS, and PD, we performed gene set enrichment analysis to identify pathways and GO of the overlapping DEGs with EnrichR \[[@B51-ijerph-17-01035]\]. Pathways are central to organism responses to stimuli, and pathway-based analysis is a recently developed approach to understand how complex diseases may be related to each other through their underlying molecular mechanisms \[[@B52-ijerph-17-01035]\]. GO is a conceptual model for the representation of gene functions and their relationship to gene regulation \[[@B53-ijerph-17-01035]\]. We considered 7 pathway databases: KEGG \[[@B54-ijerph-17-01035]\], Reactome \[[@B55-ijerph-17-01035]\], NCI-Nature \[[@B56-ijerph-17-01035]\], WiKi \[[@B57-ijerph-17-01035]\], BioCarta \[[@B58-ijerph-17-01035]\], Panther \[[@B59-ijerph-17-01035]\] and HumanCyc pathway database \[[@B60-ijerph-17-01035]\] and Gene ontology (GO) domain: Biological Process (BP).

2.4. Protein-Protein Interactions Analysis {#sec2dot4-ijerph-17-01035}
------------------------------------------

Protein-protein interaction networks (PPIs) represent the physical contacts between two or more proteins molecules and are essential to all cell processes \[[@B61-ijerph-17-01035]\]. We also generated protein-protein interaction (PPI) networks based on the physical interaction of the proteins of DEGs by using information from the STRING database \[[@B62-ijerph-17-01035]\] via Network Analyst using the confidence score 900, where proteins are represented by nodes and protein interactions represented by edges. Using topological parameters, for example, a degree greater than 15°, highly interacting proteins were identified from PPI analysis.

2.5. Transcription Factors-microRNA Interactions Analysis {#sec2dot5-ijerph-17-01035}
---------------------------------------------------------

We studied the DEGs-Transcription Factors (TFs) and DEGs-microRNAs (miRNAs) to identify the regulatory biomolecules (i.e., TFs and miRNAs) that regulate DEGs of interest at the transcriptional and post-transcriptional level. We utilized the JASPAR database to analyze the DEGs-TFs interaction \[[@B63-ijerph-17-01035]\]. We employed miRNA-DEGs interactions from TarBase \[[@B64-ijerph-17-01035]\] and miRTarBase \[[@B65-ijerph-17-01035]\]. The topological analysis was performed via Network Analyzer in Cytoscape \[[@B47-ijerph-17-01035]\] and Network Analyst \[[@B66-ijerph-17-01035]\]. The TFs were screened out based on the degree (≥20) from the DEGs-TFs network. The miRNAs were selected based on the degree (≥15) from the DEGs-miRNAs network.

2.6. An Overview of the Analytical Approach {#sec2dot6-ijerph-17-01035}
-------------------------------------------

Our network-based systematical and quantitative pipeline to evaluate gene expression in human disease comorbidities is summarized as shown in [Figure 1](#ijerph-17-01035-f001){ref-type="fig"}. The integrated pipeline of used here was implemented using the R language, code which is available on request. We developed the proposed pipeline using GEOquery \[[@B67-ijerph-17-01035]\] for downloading GEO datasets and expression set class transformation; limma \[[@B46-ijerph-17-01035]\] for differentially expressed gene identification from microarray data; genefilter \[[@B68-ijerph-17-01035]\] for filtering genes. The version of the used software and packages was R version 3.5.1, R Studio 1.0.136, Bioconductor 3.8, GEOquery 2.50.5, Affy 1.56.0, limma 3.38.3, genefilter 1.64.0.

Our approach employs gene expression analyses, disease gene association networks, signaling pathway mechanisms, gene ontology (GO) data, protein-protein interactions (PPIs) network, DEGs-Transcription Factors (TFs) interaction analysis, and DEGs-MicroRNAs (miRNAs) interaction analysis to identify putative discriminatory biomarkers between T2D and NDs. Furthermore, we also incorporated three gold benchmark verified datasets, OMIM ([www.omim.org](www.omim.org)), OMIM Expanded, and dbGaP ([www.ncbi.nlm.nih.gov/gap](www.ncbi.nlm.nih.gov/gap)) to retrieve genes associated with known diseases and relevant disorders for validating the proof of principle of our network-based approach.

3. Results {#sec3-ijerph-17-01035}
==========

3.1. Gene Expression Analysis {#sec3dot1-ijerph-17-01035}
-----------------------------

To identify and investigate the gene expression effects of T2D that may influence the progression of NDs, we analyzed the gene expression microarray data collected from the National Center for Biotechnology Information (NCBI). Based on significant *p*-values, we found 1320 DEGs for T2D with false discovery rate (FDR) of 0.01 and absolute logFC of 1 using R Bioconductor packages (Limma). Similarly, we identified the most significant DEGs for each ND after statistical analysis. We identified 1606 DEGs in AD, 2901 in ALS, 588 in CP, 1887 in ED, 1338 in HD, 7463 in MS and 1558 in PD which is shown in [Table 1](#ijerph-17-01035-t001){ref-type="table"}.

The cross-comparison analysis also identified common DEGs between T2D and each ND. We found that T2D shares 5, 5, 11, 15, 7, 35 and 21 significantly up-regulated genes whereas 12, 25, 6, 16, 7, 29 and 3 significant down-regulated genes for the AD, ALS, CP, ED, HD, MS, and PD respectively. To get statistically significant associations between T2D and the NDs, we built up- and down-regulated diseasome relationships network centered on the T2D and a link indicated between a disease and a gene when mutations in that gene are known to lead to the specific disease, as shown in [Figure 2](#ijerph-17-01035-f002){ref-type="fig"} and [Figure 3](#ijerph-17-01035-f003){ref-type="fig"} whereas two diseases are comorbid, if they share associated genes.

The most important up-regulated overlapping genes are as follows: (a) FLI1, PACSIN2, BICD1, TCP11L2, and ENTPD1 among T2D, ED, and MS, (b) PEG10 and EFCAB14 among T2D, PD, and MS, (c) ITGB8 among T2D, HD, PD, and MS, (d) FBLN1 among T2D, ALS, and MS, (e) IGFBP5 among T2D, CP, and MS, (f) SGCB among T2D, HD, and MS, (g) SLC25A30 among T2D, PD, and CP. The significant down-regulated overlapping genes are as follows: (a) ST6GALNAC5 and RIMS1 among T2D, AD, and MS, (b) ZBTB7A and YME1L1 among T2D, ALS, and ED, (c) FUT6 among T2D, AD, and ALS, (d) BRF1 among T2D, ALS, and CP, (e) CDC14B among T2D, ALS, ED, and MS, (f) CD47 among T2D, ALS, HD, and ED, (g) NRG1 among T2D, ALS, HD, and MS, (h) DNM1 among T2D, CP, and MS, (i) TLB1XR1 among T2D, HD, and MS, and (j) GPR161 among T2D, ALS, and MS.

3.2. Pathway and Functional Association Analysis {#sec3dot2-ijerph-17-01035}
------------------------------------------------

We performed pathways analysis to identify how complex diseases are interrelated with other diseases by the underlying molecular mechanisms. We performed gene set enrichment analysis to identify pathways using a bioinformatics resource: EnrichR \[[@B51-ijerph-17-01035]\] and considered 7 pathways databases to carry out tests using DEGs common between T2D and each ND. We also performed the regulatory analysis to get more insights into the molecular pathways involved in these comorbidities. We pinpointed overrepresented pathways among DEGs common to T2D and NDs and classified them into functional categories. Pathways deemed significantly enriched in the common DEG sets were reduced by manual curation to include only those pathways which have a *p*-value of below 0.05. We retrieved significant pathways by EnrichR which are significantly connected with DEGs of T2D and NDs as shown in [Table 2](#ijerph-17-01035-t002){ref-type="table"}.

Among the identified pathways, we found that cytokine-cytokine receptor interaction pathway associated with adaptive inflammatory host defenses, cell growth, differentiation, cell death \[[@B54-ijerph-17-01035]\]. Glycosphingolipid biosynthesis pathway is associated with abundant amphipathic lipids expression in the nervous system \[[@B54-ijerph-17-01035]\]; Ubiquitin proteasome pathway associated with immune response and inflammation, neural and muscular degeneration, morphogenesis of neural networks and response to stress and extracellular modulators \[[@B59-ijerph-17-01035]\]; Ionotropic glutamate receptor pathway associated with the mediatation of the majority of excitatory synaptic transmission throughout the central nervous system and synaptic plasticity \[[@B59-ijerph-17-01035]\]; Glutamate neurotransmitter release cycle maintains the neurotransmitter glutamate in the central nervous system \[[@B55-ijerph-17-01035]\]; Transmission across chemical synapses pathway associated with the communication between neurons, muscle or gland cells \[[@B55-ijerph-17-01035]\]; Glutamatergic synapse pathway associated with the regulation of several neuronal functions, such as neuronal migration, excitability, plasticity, long-term potentiation (LTP) and long-term depression (LTD) \[[@B57-ijerph-17-01035]\]; Neuronal system pathway comprised of at least 100 billion neurons are associated with the communication among astronomical number of elements with functional connection between neurons \[[@B55-ijerph-17-01035]\]; Cell adhesion molecules (CAMs) pathway associated with a vital role in the development and maintenance of the nervous system \[[@B54-ijerph-17-01035]\]; Electric transmission across gap junctions pathway associated with the function of communicating neurons in the nervous systems \[[@B55-ijerph-17-01035]\]; Transmission across electrical synapses pathway associated with the mechanical conductive link between two neighboring neurons \[[@B55-ijerph-17-01035]\]; Spinal cord injury pathway associated with the loss of muscle function, sensation, or autonomic function in the parts of the body \[[@B57-ijerph-17-01035]\]; Neurotrophic factor-mediated Trk receptor signaling pathway associated with neuronal differentiation, survival and growth \[[@B56-ijerph-17-01035]\]; Neurotrophin signaling pathway associated with differentiation and survival of neural cells \[[@B54-ijerph-17-01035]\]; Adipocytokine signaling pathway associated with the process of inflammation, coagulation, fibrinolysis, insulin resistance, diabetes and atherosclerosis \[[@B54-ijerph-17-01035]\]; Brain-derived neurotrophic factor (BDNF) signaling pathway associated with growth, differentiation, plasticity, and survival of neurons. BDNF is also implicated in various neuronal disorders such as Alzheimer's disease, Huntington's disease \[[@B57-ijerph-17-01035]\].

To obtain further insights into the molecular roles and biological significance, enriched common DEGs sets were processed by GO methods using Enrichr, which identifies related biological processes (BP) in order to group them in functional categories. The list of processes and terms was then curated to include those terms with a *p*-value below 0.05. The cell processes thus identified are summarized in [Table 3](#ijerph-17-01035-t003){ref-type="table"}.

3.3. Protein-Protein Interactions (PPIs) Analysis {#sec3dot3-ijerph-17-01035}
-------------------------------------------------

Using our enriched common disease genesets, we constructed putative PPI networks with web-based visualization resource STRING via Network Analyst using the confidence score 900 by the distinct 159 DEGs, as shown in [Figure 4](#ijerph-17-01035-f004){ref-type="fig"}. The PPIs make up the so-called interactomics of the organism where anomalous PPIs cause multiple diseases. Two diseases are known to be related where one or more commonly associated protein subnetworks are shared. Using topological parameters, for example, the degree greater than 15°, highly interacting proteins were identified from PPI analysis.

The simplified PPI networks were generated with the Cyto-Hubba plugin \[[@B69-ijerph-17-01035]\] to identify the most significant hub proteins as shown in [Table 4](#ijerph-17-01035-t004){ref-type="table"} and the topological parameters were determined by Network Analyzer in Cytoscape \[[@B47-ijerph-17-01035]\] as shown in [Figure 5](#ijerph-17-01035-f005){ref-type="fig"}.

This data provides evidence that PPI subnetwork exists in our enriched genesets and confirms the inclusion of relevant functional pathways. These identified hub proteins could be useful for therapeutic targets although further characterization is needed for their roles. The summary of hub protein is shown in [Table 4](#ijerph-17-01035-t004){ref-type="table"}.

3.4. Identification of Transcriptional and Post-Transcriptional Regulators of the Differentially Expressed Genes {#sec3dot4-ijerph-17-01035}
----------------------------------------------------------------------------------------------------------------

TFs are proteins that regulate transcriptional and gene expression in all living organisms. TFs play a vital role in all cellular processes \[[@B70-ijerph-17-01035]\]. miRNAs are short RNA species involved in the post-transcriptional regulation of gene expression. The miRNAs are important biological regulators, for instance, neuronal differentiation, neurogenesis, and synaptic plasticity and they play vital roles in neurodegenerative diseases \[[@B71-ijerph-17-01035]\].

To identify the transcriptional and/or -post-transcriptional regulators of the DEGs, we performed the interaction of the DEGs-TFs analysis as shown in [Figure 6](#ijerph-17-01035-f006){ref-type="fig"} and DEGs-miRNAs interaction analysis as shown in [Figure 7](#ijerph-17-01035-f007){ref-type="fig"}.

The biomolecules (i.e., TFs and miRNAs) are summarized in [Table 5](#ijerph-17-01035-t005){ref-type="table"}. The FOXC1, GATA2, FOXL1, YY1, E2F1, NFIC, NFYA, USF2, HINFP, MEF2A, SRF, NFKB1, USF2, HINFP, MEF2A, SRF, NFKB1, PDE4D, CREB1, SP1, HOXA5, SREBF1, TFAP2A, STAT3, POU2F2, TP53, PPARG, JUN were identified as the key regulators of the identified DEGs.

The miRNAs (mir-335-5p, mir-16-5p, mir-93-5p, mir-17-5p, mir-124-3p) were identified to provide an in-depth understanding of the DEGs at post-transcriptional regulators. The summary of transcriptional and/or post-transcriptional regulatory biomolecules of differentially expressed genes that are common to T2D and NDs is shown in [Table 5](#ijerph-17-01035-t005){ref-type="table"}.

3.5. Validating Potential Targets Using Gold Benchmark Databases and Literatures {#sec3dot5-ijerph-17-01035}
--------------------------------------------------------------------------------

First of all, to validate our identified potential targets, we used OMIM, OMIM Expanded, and dbGaP datasets; these datasets collect curated and validated genes that indicate disease association data from the literature. In the validation, we presented a combined relation of OMIM, OMIM Expanded, and dbGaP databases. For evaluating the validity of our work, we provided statistically significant DEGs (genes common to T2D and neurological diseases (NDs)) to the online tool EnrichR \[[@B51-ijerph-17-01035]\] and collected enriched genes and their corresponding neurological disease names from OMIM, OMIM Expanded, and dbGaP databases. To find significant NDs, manual curation is applied considering a *p*-value of 0.05. Then, several diseases such as cancer, infectious diseases are removed from this list because they are not of interest in this study.

We also validated our identified potential targets by checking the biomedical literature to find genes clinically used as biomarkers for any of the NDs. We found that Van Cauwenberghe et al. \[[@B72-ijerph-17-01035]\] identified the MS4A2 gene associated with AD and Munshi et al. \[[@B73-ijerph-17-01035]\] identified the CR1 gene associated with AD. Eykens et al. \[[@B74-ijerph-17-01035]\] identified the APOE gene associated with ALS. Fahey et al. \[[@B75-ijerph-17-01035]\] identified the TENM1 gene associated with CP. UBE3A and CHD2 genes are associated with ED \[[@B76-ijerph-17-01035],[@B77-ijerph-17-01035]\]. Arning et al. identified the UCHL1 \[[@B78-ijerph-17-01035]\] gene associated with HD. Baranzini et al. \[[@B79-ijerph-17-01035]\] identified the HLA-DRB1 gene to be associated with MS. Redenšek et al. identified \[[@B80-ijerph-17-01035]\] the HLA-DQB1 gene as associated with PD. This indicates that our analyses of significant genes in NDs match with existing records. We then constructed a Gene-Disease Network (GDN) based on genes and their associated neurological diseases from gold benchmark databases and literature using Cytoscape. This network showed gene-disease associations whereby if a gene mutation is known to lead to a specific disease, a link is indicated between disease and gene; this is shown in [Figure 8](#ijerph-17-01035-f008){ref-type="fig"}.

4. Discussion {#sec4-ijerph-17-01035}
=============

T2D and NDs are complex diseases but we have attempted here to take advantage of this complexity by looking at pathway and looking at interactions between type 2 diabetes (T2D) and neurological diseases, due to their great clinical importance. T2D is known to affect neurological diseases but how it does this is generally unclear (though some vascular based mechanisms are usually considered) and it is very hard to study by hypothesis-driven biochical or endocrinological research. This is why we employed well-established bioinformatics methods and analytical approaches that examine functional disease overlaps in genes and pathways, and provide an important but agnostic tool to identify new factors that play a part in these comorbidity interactions and which, by implication, may be important pathogenic mechanisms for these and other related diseases. We studied the microarray gene expression datasets from publicly available repositories employing a network-based bioinformatics pipeline. We identified DEGs common to T2D and NDs and constructed diseasome networks to provide insights into the interactions of these comorbidities using the diesease-common DEGs. These DEGs enabled identification of associated dysregulated molecular pathways and related GO terms. One particular technical point is that a large number of pathways and GO categories were reduced by manual curation after filtering using a *p*-value threshold of 0.05. We identified different pathways by investigating cell proteins (i.e., gene products) and their interactions considering seven pathway databases.

In addition to the pathways and GO terms we investigated interactors of the products of our DEGs of interest using protein-protein interaction (PPI) analysis and hub protein identification as well as DEGs-TFs, and DEGs-miRNAs interaction that has not been previously studied for these diseases. These studies' provide information about the molecules that could be the key drivers of pathogenesis for these comorbidities. The STRING database contains known protein-protein interactions which we used to identify the PPI for products of our genes of interest. For our purpose, we considered only experimentally verified PPI data, not predicted PPIs. We reconstructed the PPI based on the identified DEGs common to T2D and NDs and identified the central hub proteins using topological parameters. Among the hub proteins we identified, dynamin (DNM1) has been implicated in central nervous systems \[[@B81-ijerph-17-01035]\] and DNM2 is involved in Charcot-Marie-Tooth neuropathy \[[@B82-ijerph-17-01035]\]. However, a role for MYH14 in diabetes or neurodegenerative diseases is not reported. PACSIN2 expression has been found to be upregulated in diabetic kidney disease \[[@B83-ijerph-17-01035]\]. Borie et al studied the polymorphism of the TFRC gene involved in Parkinson's disease \[[@B84-ijerph-17-01035]\]. Rahman et al. identified PDE4D commonly expressed in blood cell and brain tissues of AD \[[@B85-ijerph-17-01035]\]. A mutation of ENTPD1 has been identified in Spastic paraplegia type 64 in individuals diagnosed with suspected neurodegenerative disease patients \[[@B86-ijerph-17-01035]\]. To date, no role for PLK4, CDC20B, and CDC14A in NDs has been reported.

Transcription factors (TFs) are critical determinants of transcription of their various target genes, so their levels can identify potential biomarkers for neurodegenerative diseases. In this study, we identified relevant TFs as the regulator of the DEGs through TF-mRNA interaction networks that are relevant to the pathogenesis of T2D and NDs. TF-association has also been used by Rahman et al. in a network-based method to profile gene expression of DEGs associated with AD; they identified a number of AD-associated TFs, including JUN, YY1, E2F1, FOXC1, GATA2, SRF, USF2, PPARG, FOXL1, and NFIC \[[@B87-ijerph-17-01035]\], consistent with the present study. In contrast to TFs, microRNAs (∼$\left. 22ntlong \right)$ act post-transcriptionally to regulate expression. These are single nucleotide RNA which bind target mRNA, leading to the target cleavage and reduced expression. These miRNAs have many advantages of non-invasive biomarkers and can be detected in body fluids such as urine, saliva and makes them potentially attractive as biomarkers. Indeed, there are miRNAs that show good potential as biomarkers for neurodegenerative diseases \[[@B88-ijerph-17-01035]\]. Thus, we studied DEGs-miRNA interaction networks to identify relevant miRNAs as potential targets for NDs. Among the identified miRNAs, the miRNA-335 was particularly associated with AD \[[@B71-ijerph-17-01035]\]. In addition, miRNA-16 was reported to be involved in apoptosis in neural cells \[[@B89-ijerph-17-01035]\]. Furthermore, the down-expression of this miRNA is involved in the accumulation of amyloid protein precursor (APP) protein in AD \[[@B90-ijerph-17-01035]\]. The miRNA-124 is found abundantly in neural cells and as known involvement in NDs. The reduced expression is miRNA associated with AD, PD, and HD \[[@B88-ijerph-17-01035]\]. There is no evidence for ND association with miR-17-5p although it has pathogenic actions both enhancing and suppressing tumour development depending on the cellular contexts \[[@B91-ijerph-17-01035]\].

The above indicates that our approach has the potential to reveal some of the important mechanisms that underlie disease pathogenesis and provide novel hypotheses of disease mechanisms and may identify new biomarkers. Such genetic data analyses will be a key element in the development of predictive medicine and elucidating the underlying mechanisms that connect T2D and NDs and may indicate possible new drug targets. Nevertheless, our data show some limitations. It should be noted that no clinical confirmation of the roles of proteins generated from our identified genes of interest. Furthermore, the low number of samples for some diseases analyzed which may not fully sample the disease-associated genes that we used to determine the common DEGs. Thus, further experimentation is needed to properly evaluate the biological significance of the identified potential targets candidates in this study.

5. Conclusions {#sec5-ijerph-17-01035}
==============

The present study analyzed transcriptomics datasets of the T2D and neurodegenerative diseases employing a multi-omics approach to decode the overlapped genes that were expressed between T2D and NDs. The gene set enrichment analysis revealed significantly enriched dysregulated pathways. Integration of the overlapped DEGs with different biomolecular interaction networks yielded 10 hub proteins form protein-protein interaction, regulatory TFs from DEG-TF interactions analysis, and miRNAs from DEGs-miRNAs interactions analysis. All of these hub genes and pathways are novel, that is, they have not previously been shown to be important in these diseases or in the disease interactions and most of the TFs and miRNAs identified are also novel. In this way, the present study presented molecular signatures at proteins level (i.e., hub proteins and TFs), and RNA levels (i.e., mRNAs, miRNAs), pathway and GO level but further studies are needed to establish them as biomarkers. These results indicate differentially expressed genes of T2D that may be key to the progression of NDs and may give new insights into these diseases. It also points the way to identifying mechanistic links between the T2D and various ND and that explains why their association with T2D. This study also suggests that T2D shares several common multifactorial degenerative biological processes that contribute to neuronal death, which may, in turn, lead to functional impairment. Additionally, we believe that our high-throughput transcript analysis of tissues using rigorous agnostic approaches would allow the discovery of disease-modifying therapeutic targets. Treatments aimed at attenuating the identified dysregulated pathways have the potential to ameliorate neurological dysfunctions in the T2D patient.
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###### 

The differentially expressed gene (DEG) for all employed Datasets in the present study.

  Disease Name                    GEO Platform                                  Tissues/Cells      GEO Accession   Raw Genes   Case Samples   Control Samples   UP Reg. Genes   Down Reg. Genes
  ------------------------------- --------------------------------------------- ------------------ --------------- ----------- -------------- ----------------- --------------- -----------------
  Type 2 Diabetes (T2D)           Affymetrix Human Genome U133 Plus 2.0 Array   Liver              GSE23343        54613       10             7                 622             698
  Alzheimer's disease             Affymetrix Human Genome U133 Plus 2.0 Array   CA1 tissue         GSE28146        54675       22             8                 847             759
  Amyotrophic lateral sclerosis   Affymetrix Human Full Length HuGeneFL Array   Spinal cord        GSE833          22277       7              5                 735             2166
  Cerebral palsy                  Affymetrix Human Genome U133 Plus 2.0 Array   Muscle             GSE31243        22277       20             20                243             345
  Epilepsy disease                Affymetrix Human Genome U133 Plus 2.0 Array   Peripheral Blood   GSE22779        54675       12             4                 882             1007
  Huntington's disease            Affymetrix Human Genome U133 Plus 2.0 Array   Whole Blood        GSE1751         22283       17             14                365             973
  Multiple sclerosis              Affymetrix Human Genome U133 Plus 2.0 Array   Brain              GSE38010        33398       5              2                 3987            3476
  Parkinson's disease             Affymetrix Human Genome U133A 2.0 Array       Brain              GSE19587        22277       12             10                1167            422

ijerph-17-01035-t002_Table 2

###### 

Pathways common to T2D and the NDs revealed by the commonly expressed genes. These include significant pathways common to (**a**) T2D and AD (**b**) T2D and ALS (**c**) T2D and CP (**d**) T2D and ED (**e**) T2D and HD (**f**) T2D and MS and (**g**) T2D and PD.

  ---------------------------------------------------------------------------------------- --------------------------------------- ------------
  (**a**) Common significant pathway common between T2D and AD                                                                     
  **Pathway Name**                                                                         ***p*** **-Value**                      **Source**
  Neuroregulin receptor degredation protein-1 Controls ErbB3 receptor recycling            3.78 $\times \mspace{600mu} 10^{- 2}$   Biocarta
  Cytokine-cytokine receptor interaction                                                   1.17 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Toll-like receptor signaling pathway                                                     2.92 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Glycosphingolipid biosynthesis                                                           3.36 $\times \mspace{600mu} 10^{- 2}$   KEGG
  IL1-mediated signaling events                                                            1.89 $\times \mspace{600mu} 10^{- 2}$   NCI-Nature
  TCR signaling in naive CD8+ T cells                                                      4.53 $\times \mspace{600mu} 10^{- 2}$   NCI-Nature
  Ubiquitin proteasome pathway                                                             3.09 $\times \mspace{600mu} 10^{- 2}$   Panther
  Ionotropic glutamate receptor pathway                                                    3.36 $\times \mspace{600mu} 10^{- 2}$   Panther
  Glutamate Neurotransmitter Release Cycle                                                 1.02 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Signaling by Interleukins                                                                1.32 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Cytokine Signaling in the Immune system                                                  1.83 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Oxidative Stress-Induced Senescence                                                      2.07 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Neurotransmitter Release Cycle                                                           4.23 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Transmission across Chemical Synapses                                                    4.68 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Apoptosis Modulation and Signaling                                                       2.97 $\times \mspace{600mu} 10^{- 4}$   Wiki
  (**b**) Common significant pathway common between T2D and ALS                                                                    
  **Pathway Name**                                                                         ***p*** **-Value**                      **Source**
  Neuroregulin receptor degredation protein-1 Controls ErbB3 receptor recycling            1.48 $\times \mspace{600mu} 10^{- 3}$   Biocarta
  Cytokine-cytokine receptor interaction                                                   3.10 $\times \mspace{600mu} 10^{- 3}$   KEGG
  Glycosphingolipid biosynthesis                                                           1.05 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Ubiquitin mediated proteolysis                                                           1.28 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Glutamatergic synapse                                                                    2.85 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Immune System                                                                            3.74 $\times \mspace{600mu} 10^{- 3}$   Reactome
  Innate Immune System                                                                     7.98 $\times \mspace{600mu} 10^{- 3}$   Reactome
  Insulin receptor signaling cascade                                                       8.94 $\times \mspace{600mu} 10^{- 3}$   Reactome
  Cytokine Signaling in the Immune system                                                  1.05 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Neuronal System                                                                          1.17 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Neurotransmitter Receptor Binding And Downstream Transmission in The Postsynaptic Cell   1.47 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Transmission across Chemical Synapses                                                    2.05 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Adaptive Immune System                                                                   2.30 $\times \mspace{600mu} 10^{- 2}$   Reactome
  NO/cGMP/PKG mediated Neuroprotection                                                     1.19 $\times \mspace{600mu} 10^{- 2}$   Wiki
  Toll-like Receptor Signaling                                                             3.90 $\times \mspace{600mu} 10^{- 2}$   Wiki
  (**c**) Common significant pathway common between T2D and CP                                                                     
  **Pathway Name**                                                                         ***p*** **-Value**                      **Source**
  Focal adhesion                                                                           4.47 $\times \mspace{600mu} 10^{- 3}$   KEGG
  Dopaminergic synapse                                                                     9.70 $\times \mspace{600mu} 10^{- 3}$   KEGG
  Cell adhesion molecules (CAMs)                                                           1.28 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Rapid glucocorticoid signaling                                                           2.65 $\times \mspace{600mu} 10^{- 2}$   NCI-Nature
  Inflammation mediated by chemokine and cytokine signaling pathway                        4.19 $\times \mspace{600mu} 10^{- 4}$   Panther
  Adaptive Immune System                                                                   7.50 $\times \mspace{600mu} 10^{- 6}$   Reactome
  Immune System                                                                            1.47 $\times \mspace{600mu} 10^{- 4}$   Reactome
  Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell   1.21 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Electric Transmission Across Gap Junctions                                               1.66 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Transmission across Electrical Synapses                                                  1.66 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Neuronal System                                                                          1.84 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Neurofascin interactions                                                                 2.32 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Transmission across Chemical Synapses                                                    3.39 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Inflammatory Response Pathway                                                            4.53 $\times \mspace{600mu} 10^{- 3}$   Wiki
  Insulin signaling in human adipocytes                                                    2.65 $\times \mspace{600mu} 10^{- 2}$   Wiki
  Toll-like Receptor Signaling Pathway                                                     4.68 $\times \mspace{600mu} 10^{- 2}$   Wiki
  (**d**) Common significant pathway common between T2D and ED                                                                     
  **Pathway Name**                                                                         ***p*** **-Value**                      **Source**
  Cell adhesion molecules (CAMs)                                                           1.14 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Ubiquitin mediated proteolysis                                                           4.95 $\times \mspace{600mu} 10^{- 2}$   KEGG
  TCR signaling in naive CD8+ T cells                                                      4.03 $\times \mspace{600mu} 10^{- 2}$   NCI-Nature
  Rapid glucocorticoid signaling                                                           4.70 $\times \mspace{600mu} 10^{- 2}$   NCI-Nature
  Apoptosis signaling pathway                                                              2.35 $\times \mspace{600mu} 10^{- 2}$   Panther
  Ubiquitin proteasome pathway                                                             2.75 $\times \mspace{600mu} 10^{- 2}$   Panther
  Adaptive Immune System                                                                   6.15 $\times \mspace{600mu} 10^{- 3}$   Reactome
  Oxidative Stress-Induced Senescence                                                      1.75 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Immune System                                                                            2.26 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Deposition of new CENPA-containing nucleosomes at the centromere                         3.90 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Spinal Cord Injury                                                                       3.42 $\times \mspace{600mu} 10^{- 2}$   Wiki
  (**e**) Common significant pathway common between T2D and HD                                                                     
  **Pathway Name**                                                                         ***p*** **-Value**                      **Source**
  Neuroregulin receptor degredation protein-1 Controls ErbB3 receptor recycling            2.59 $\times \mspace{600mu} 10^{- 4}$   Biocarta
  Glycosphingolipid biosynthesis                                                           1.54 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Cell adhesion molecules (CAMs)                                                           2.32 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Cytokine-cytokine receptor interaction                                                   3.53 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Neurotrophic factor-mediated Trk receptor signaling                                      2.72 $\times \mspace{600mu} 10^{- 2}$   NCI-Nature
  Ubiquitin proteasome pathway                                                             1.41 $\times \mspace{600mu} 10^{- 2}$   Panther
  Cholesterol biosynthesis                                                                 4.53 $\times \mspace{600mu} 10^{- 2}$   Panther
  Immune System                                                                            1.82 $\times \mspace{600mu} 10^{- 3}$   Reactome
  Cytokine Signaling in the Immune system                                                  1.54 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Innate Immune System                                                                     2.00 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Adaptive Immune System                                                                   4.10 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Toll-Like Receptors Cascades                                                             2.12 $\times \mspace{600mu} 10^{- 2}$   Reactome
  NO/cGMP/PKG mediated Neuroprotection                                                     1.67 $\times \mspace{600mu} 10^{- 2}$   Wiki
  Apoptosis                                                                                4.87 $\times \mspace{600mu} 10^{- 2}$   Wiki
  Tryptophan metabolism                                                                    1.60 $\times \mspace{600mu} 10^{- 2}$   Wiki
  (**f**) Common significant pathway common between T2D and MS                                                                     
  **Pathway Name**                                                                         ***p*** **-Value**                      **Source**
  Neurotrophin signaling pathway                                                           1.17 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Glycosphingolipid biosynthesis                                                           1.36 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Adipocytokine signaling pathway                                                          1.39 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Autophagy                                                                                1.69 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Glutamatergic synapse                                                                    3.07 $\times \mspace{600mu} 10^{- 2}$   KEGG
  GABAergic synapse                                                                        3.68 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Neurotrophic factor-mediated Trk receptor signaling                                      8.37 $\times \mspace{600mu} 10^{- 3}$   NCI-Nature
  Insulin/IGF pathway-protein kinase B signaling cascade                                   5.05 $\times \mspace{600mu} 10^{- 3}$   Panther
  Apoptosis signaling pathway                                                              5.17 $\times \mspace{600mu} 10^{- 3}$   Panther
  Ubiquitin proteasome pathway                                                             1.16 $\times \mspace{600mu} 10^{- 2}$   Panther
  Ionotropic glutamate receptor pathway                                                    1.36 $\times \mspace{600mu} 10^{- 2}$   Panther
  Transmission across Chemical Synapses                                                    8.34 $\times \mspace{600mu} 10^{- 6}$   Reactome
  Neuronal System                                                                          1.71 $\times \mspace{600mu} 10^{- 5}$   Reactome
  Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell   1.77 $\times \mspace{600mu} 10^{- 4}$   Reactome
  Insulin receptor signaling cascade                                                       2.65 $\times \mspace{600mu} 10^{- 3}$   Reactome
  Oxidative Stress-Induced Senescence                                                      1.13 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Brain-Derived Neurotrophic Factor (BDNF) signaling pathway                               2.98 $\times \mspace{600mu} 10^{- 2}$   Wiki
  (**g**) Common significant pathway common between T2D and PD                                                                     
  **Pathway Name**                                                                         ***p*** **-Value**                      **Source**
  Neuroregulin receptor degredation protein-1 Controls ErbB3 receptor recycling            4.04 $\times \mspace{600mu} 10^{- 4}$   Biocarta
  Toll-like receptor signaling pathway                                                     2.21 $\times \mspace{600mu} 10^{- 3}$   KEGG
  Cell adhesion molecules (CAMs)                                                           7.20 $\times \mspace{600mu} 10^{- 3}$   KEGG
  Allograft rejection                                                                      1.70 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Graft-versus-host disease                                                                1.96 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Intestinal immune network for IgA production                                             2.63 $\times \mspace{600mu} 10^{- 2}$   KEGG
  Innate Immune System                                                                     1.07 $\times \mspace{600mu} 10^{- 3}$   Reactome
  Insulin receptor signaling cascade                                                       4.07 $\times \mspace{600mu} 10^{- 3}$   Reactome
  Immune System                                                                            1.50 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Chemokine receptors bind chemokines                                                      3.50 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Adaptive Immune System                                                                   4.73 $\times \mspace{600mu} 10^{- 2}$   Reactome
  Transmission across Electrical Synapses                                                  2.60 $\times \mspace{600mu} 10^{- 2}$   Reactome
  ---------------------------------------------------------------------------------------- --------------------------------------- ------------
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###### 

Gene ontology identification of biological processes common to (**a**) T2D and AD (**b**) T2D and ALS (**c**) T2D and CP (**d**) T2D and ED (**e**) T2D and HD (**f**) T2D and MS and (**g**) T2D and PD.

  ----------------------------------------------- -------------------------------------------------------------------- ---------------------------------------
  (**a**) Common significant GOs of T2D and AD                                                                         
  **GO ID**                                       **Pathway**                                                          ***p*** **-Value**
  GO:0032000                                      positive regulation of fatty acid beta-oxidation                     5.99 $\times \mspace{600mu} 10^{- 3}$
  GO:0016064                                      immunoglobulin mediated immune response                              6.73 $\times \mspace{600mu} 10^{- 3}$
  GO:2000269                                      regulation of fibroblast apoptotic process                           6.73 $\times \mspace{600mu} 10^{- 3}$
  GO:0031998                                      regulation of fatty acid beta-oxidation                              8.22 $\times \mspace{600mu} 10^{- 3}$
  GO:0051588                                      regulation of neurotransmitter transport                             1.05 $\times \mspace{600mu} 10^{- 2}$
  GO:0007498                                      mesoderm development                                                 1.64 $\times \mspace{600mu} 10^{- 2}$
  GO:0051961                                      negative regulation of nervous system development                    1.71 $\times \mspace{600mu} 10^{- 2}$
  GO:0046928                                      regulation of neurotransmitter secretion                             2.08 $\times \mspace{600mu} 10^{- 2}$
  (**b**) Common significant GOs of T2D and ALS                                                                        
  **GO ID**                                       **Pathway**                                                          ***p*** **-Value**
  GO:0006352                                      DNA-templated transcription, initiation                              2.46 $\times \mspace{600mu} 10^{- 3}$
  GO:0050870                                      positive regulation of T cell activation                             4.48 $\times \mspace{600mu} 10^{- 3}$
  GO:0048935                                      peripheral nervous system neuron development                         1.01 $\times \mspace{600mu} 10^{- 2}$
  GO:0021522                                      spinal cord motor neuron differentiation                             1.01 $\times \mspace{600mu} 10^{- 2}$
  GO:0021559                                      trigeminal nerve development                                         1.01 $\times \mspace{600mu} 10^{- 2}$
  GO:2000145                                      regulation of cell motility                                          1.10 $\times \mspace{600mu} 10^{- 2}$
  GO:0048665                                      neuron fate specification                                            1.15 $\times \mspace{600mu} 10^{- 2}$
  GO:1902692                                      regulation of neuroblast proliferation                               1.58 $\times \mspace{600mu} 10^{- 2}$
  GO:0048663                                      neuron fate commitment                                               2.01 $\times \mspace{600mu} 10^{- 2}$
  GO:2000177                                      regulation of neural precursor cell proliferation                    2.15 $\times \mspace{600mu} 10^{- 2}$
  GO:0014033                                      neural crest cell differentiation                                    2.30 $\times \mspace{600mu} 10^{- 2}$
  GO:0045597                                      positive regulation of cell differentiation                          3.23 $\times \mspace{600mu} 10^{- 2}$
  GO:0051961                                      negative regulation of nervous system development                    3.28 $\times \mspace{600mu} 10^{- 2}$
  GO:0019228                                      neuronal action potential                                            3.42 $\times \mspace{600mu} 10^{- 2}$
  GO:0021953                                      central nervous system neuron differentiation                        4.68 $\times \mspace{600mu} 10^{- 2}$
  GO:0050768                                      negative regulation of neurogenesis                                  4.82 $\times \mspace{600mu} 10^{- 2}$
  (**c**) Common significant GOs of T2D and CP                                                                         
  **GO ID**                                       **Pathway**                                                          ***p*** **-Value**
  GO:0071363                                      cellular response to growth factor stimulus                          5.47 $\times \mspace{600mu} 10^{- 3}$
  GO:0048681                                      negative regulation of axon regeneration                             6.38 $\times \mspace{600mu} 10^{- 3}$
  GO:0070571                                      negative regulation of neuron projection regeneration                7.18 $\times \mspace{600mu} 10^{- 3}$
  GO:0099590                                      neurotransmitter receptor internalization                            8.77 $\times \mspace{600mu} 10^{- 3}$
  GO:0048679                                      regulation of axon regeneration                                      8.77 $\times \mspace{600mu} 10^{- 3}$
  GO:0021952                                      central nervous system projection neuron axonogenesis                8.77 $\times \mspace{600mu} 10^{- 3}$
  GO:0008045                                      motor neuron axon guidance                                           8.77 $\times \mspace{600mu} 10^{- 3}$
  GO:0106030                                      neuron projection fasciculation                                      8.77 $\times \mspace{600mu} 10^{- 3}$
  GO:0071880                                      adenylate cyclase-activating adrenergic receptor signaling pathway   1.67 $\times \mspace{600mu} 10^{- 2}$
  GO:0071875                                      adrenergic receptor signaling pathway                                1.67 $\times \mspace{600mu} 10^{- 2}$
  GO:1990090                                      cellular response to nerve growth factor stimulus                    1.82 $\times \mspace{600mu} 10^{- 2}$
  GO:0010977                                      negative regulation of neuron projection development                 4.08 $\times \mspace{600mu} 10^{- 2}$
  GO:0016192                                      vesicle-mediated transport                                           4.18 $\times \mspace{600mu} 10^{- 2}$
  GO:0001934                                      positive regulation of protein phosphorylation                       4.22 $\times \mspace{600mu} 10^{- 2}$
  (**d**) Common significant GOs of T2D and ED                                                                         
  **GO ID**                                       **Pathway**                                                          ***p*** **-Value**
  GO:0006897                                      endocytosis                                                          6.45 $\times \mspace{600mu} 10^{- 3}$
  GO:0007599                                      hemostasis                                                           1.15 $\times \mspace{600mu} 10^{- 2}$
  GO:0090286                                      cytoskeletal anchoring at the nuclear membrane                       1.30 $\times \mspace{600mu} 10^{- 2}$
  GO:0034214                                      protein hexamerization                                               1.44 $\times \mspace{600mu} 10^{- 2}$
  GO:0034063                                      stress granule assembly                                              1.73 $\times \mspace{600mu} 10^{- 2}$
  GO:0097205                                      renal filtration                                                     1.73 $\times \mspace{600mu} 10^{- 2}$
  GO:0035278                                      miRNA mediated inhibition of translation                             1.73 $\times \mspace{600mu} 10^{- 2}$
  GO:0071470                                      cellular response to osmotic stress                                  2.15 $\times \mspace{600mu} 10^{- 2}$
  GO:0034656                                      nucleobase-containing small molecule catabolic process               2.30 $\times \mspace{600mu} 10^{- 2}$
  GO:0021953                                      central nervous system neuron differentiation                        4.68 $\times \mspace{600mu} 10^{- 2}$
  (**e**) Common significant GOs of T2D and HD                                                                         
  **GO ID**                                       **Pathway**                                                          ***p*** **-Value**
  GO:0042127                                      regulation of cell proliferation                                     6.92 $\times \mspace{600mu} 10^{- 5}$
  GO:0022409                                      positive regulation of cell-cell adhesion                            2.16 $\times \mspace{600mu} 10^{- 4}$
  GO:0048665                                      neuron fate specification                                            5.19 $\times \mspace{600mu} 10^{- 3}$
  GO:0048663                                      neuron fate commitment                                               9.06 $\times \mspace{600mu} 10^{- 3}$
  GO:0014033                                      neural crest cell differentiation                                    1.04 $\times \mspace{600mu} 10^{- 2}$
  GO:0043161                                      proteasome-mediated ubiquitin-dependent protein catabolic process    1.49 $\times \mspace{600mu} 10^{- 2}$
  GO:0007169                                      transmembrane receptor protein tyrosine kinase signaling pathway     2.65 $\times \mspace{600mu} 10^{- 2}$
  GO:0007399                                      nervous system development                                           3.43 $\times \mspace{600mu} 10^{- 2}$
  (**f**) Common significant GOs of T2D and MS                                                                         
  **GO ID**                                       **Pathway**                                                          ***p*** **-Value**
  GO:0070229                                      negative regulation of lymphocyte apoptotic process                  4.32 $\times \mspace{600mu} 10^{- 4}$
  GO:0099590                                      neurotransmitter receptor internalization                            5.27 $\times \mspace{600mu} 10^{- 4}$
  GO:0051588                                      regulation of neurotransmitter transport                             8.67 $\times \mspace{600mu} 10^{- 4}$
  GO:0050804                                      modulation of chemical synaptic transmission                         2.29 $\times \mspace{600mu} 10^{- 3}$
  GO:0046928                                      regulation of neurotransmitter secretion                             3.50 $\times \mspace{600mu} 10^{- 3}$
  GO:2000146                                      negative regulation of cell motility                                 3.66 $\times \mspace{600mu} 10^{- 3}$
  GO:0090181                                      regulation of cholesterol metabolic process                          7.75 $\times \mspace{600mu} 10^{- 3}$
  GO:0072657                                      protein localization to membrane                                     1.43 $\times \mspace{600mu} 10^{- 2}$
  GO:0007005                                      mitochondrion organization                                           1.60 $\times \mspace{600mu} 10^{- 2}$
  GO:0010595                                      positive regulation of endothelial cell migration                    2.11 $\times \mspace{600mu} 10^{- 2}$
  GO:0010646                                      regulation of cell communication                                     2.17 $\times \mspace{600mu} 10^{- 2}$
  GO:0050658                                      RNA transport                                                        2.70 $\times \mspace{600mu} 10^{- 2}$
  GO:0010628                                      positive regulation of gene expression                               3.43 $\times \mspace{600mu} 10^{- 2}$
  GO:2000145                                      regulation of cell motility                                          4.71 $\times \mspace{600mu} 10^{- 2}$
  GO:0014033                                      neural crest cell differentiation                                    4.92 $\times \mspace{600mu} 10^{- 2}$
  (**g**) Common significant GOs of T2D and PD                                                                         
  **GO ID**                                       **Pathway**                                                          ***p*** **-Value**
  GO:0070486                                      leukocyte aggregation                                                9.16 $\times \mspace{600mu} 10^{- 3}$
  GO:0070584                                      mitochondrion morphogenesis                                          1.14 $\times \mspace{600mu} 10^{- 2}$
  GO:0090128                                      regulation of synapse maturation                                     1.26 $\times \mspace{600mu} 10^{- 2}$
  GO:0045624                                      positive regulation of T-helper cell differentiation                 1.37 $\times \mspace{600mu} 10^{- 2}$
  GO:0048854                                      brain morphogenesis                                                  1.37 $\times \mspace{600mu} 10^{- 2}$
  GO:0019228                                      neuronal action potential                                            2.73 $\times \mspace{600mu} 10^{- 2}$
  GO:0097061                                      dendritic spine organization                                         2.84 $\times \mspace{600mu} 10^{- 2}$
  GO:0030199                                      collagen fibril organization                                         3.40 $\times \mspace{600mu} 10^{- 2}$
  GO:0061448                                      connective tissue development                                        3.51 $\times \mspace{600mu} 10^{- 2}$
  GO:0048813                                      dendrite morphogenesis                                               3.73 $\times \mspace{600mu} 10^{- 2}$
  GO:0099601                                      regulation of neurotransmitter receptor activity                     3.84 $\times \mspace{600mu} 10^{- 2}$
  ----------------------------------------------- -------------------------------------------------------------------- ---------------------------------------
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###### 

Summary of hub proteins identified by protein-protein interaction analysis encoded by DEGs that are common to type 2 diabetes (T2D) and neurological diseases (NDs).

  Protein Symbol   Degree   Description                                               Feature
  ---------------- -------- --------------------------------------------------------- --------------------------------------------------------------
  DNM1             65       Dynamin 1                                                 GTP binding
  DNM2             84       Dynamin 2                                                 GTP binding and GTPase activity
  MYH14            82       Myosin Heavy Chain 14                                     Calmodulin binding and motor activity
  PACSIN2          60       Protein Kinase C And Casein Kinase Substrate In Neurons   Identical protein binding and lipid binding
  TFRC             10       Transferrin Receptor                                      Double-stranded RNA binding
  PDE4D            39       Phosphodiesterase 4D                                      Enzyme binding and protein domain specific binding
  ENTPD1           32       Ectonucleoside Triphosphate Diphosphohydrolase 1          Hydrolase activity and nucleoside-diphosphatase activity
  PLK4             45       Polo Like Kinase 4                                        Identical protein binding and protein kinase activity
  CDC20B           20       Cell Division Cycle 20B                                   Pathways related to DNA damage response
  CDC14A           36       Cell Division Cycle 14A                                   Phosphatase activity and phosphoprotein phosphatase activity
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###### 

Summary of transcriptional and/or post-transcriptional post regulatory biomolecules of differentially expressed genes overlapped between type 2 diabetes (T2D) and neurological diseases (NDs) that includes (**a**) Regulatory Transcription Factors and (**b**) Regulatory microRNAs.

  ------------------------------------------ ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------
  (**a**) Regulatory Transcription Factors                                                              
  **Symbol**                                 **Description**                                            **Feature**
  FOXC1                                      Forkhead Box C1                                            NA-binding transcription factor activity and transcription factor binding
  GATA2                                      GATA binding protein 2                                     DNA-binding transcription factor activity and chromatin binding
  FOXL1                                      Forkhead Box L1                                            NA-binding transcription factor activity and DNA-binding transcription factor activity, RNA polymerase II-specific
  YY1                                        YY1 Transcription Factor                                   NA-binding transcription factor activity and transcription coactivator activity
  E2F1                                       E2F transcription factor 1                                 DNA-binding transcription factor activity and transcription factor binding.
  NFIC                                       Nuclear Factor I C                                         DNA-binding transcription factor activity and proximal promoter DNA-binding transcription activator activity, RNA polymerase II-specific
  NFYA                                       Nuclear Transcription Factor Y Subunit Alpha               DNA-binding transcription factor activity and transcription regulatory region DNA binding
  USF2                                       Upstream Transcription Factor 2, C-Fos Interacting         DNA-binding transcription factor activity and sequence-specific DNA binding
  HINFP                                      Histone H4 Transcription Factor                            DNA-binding transcription factor activity and enzyme binding
  MEF2A                                      Myocyte Enhancer Factor 2A                                 DNA-binding transcription factor activity and protein heterodimerization activity
  SRF                                        Serum Response Factor                                      DNA-binding transcription factor activity and sequence-specific DNA binding
  NFKB1                                      Nuclear Factor Kappa B Subunit 1                           DNA-binding transcription factor activity and sequence-specific DNA binding
  PDE4D                                      Phosphodiesterase 4D                                       enzyme binding and protein domain specific binding
  CREB1                                      CAMP Responsive Element Binding Protein 1                  DNA-binding transcription factor activity and enzyme binding
  SP1                                        Sp1 Transcription Factor                                   DNA-binding transcription factor activity and sequence-specific DNA binding
  HOXA5                                      Homeobox A5                                                DNA-binding transcription factor activity and RNA polymerase II proximal promoter sequence-specific DNA binding
  SREBF1                                     Sterol Regulatory Element Binding Transcription Factor 1   DNA-binding transcription factor activity and chromatin binding
  TFAP2A                                     Transcription Factor AP-2 Alpha                            DNA-binding transcription factor activity and sequence-specific DNA binding
  STAT3                                      Signal Transducer And Activator Of Transcription 3         DNA-binding transcription factor activity and sequence-specific DNA binding
  POU2F2                                     POU Class 2 Homeobox 2                                     DNA-binding transcription factor activity and protein domain specific binding
  TP53                                       Tumor Protein P53                                          NA-binding transcription factor activity and protein heterodimerization activity
  PPARG                                      Peroxisome Proliferator Activated Receptor Gamma           DNA-binding transcription factor activity and chromatin binding
  JUN                                        Jun Proto-Oncogene, AP-1 Transcription Factor Subunit      sequence-specific DNA binding
  (**b**) Regulatory microRNAs                                                                          
  **Symbol**                                 **Description**                                            **Feature**
  mir-335-5p                                 MicroRNA 335                                               Afflicted with Alzheimer's disease
  mir-16-5p                                  MicroRNA 16                                                Afflicted with apoptosis of neural cells
  mir-93-5p                                  MicroRNA 93                                                Involved in DNA damage pathways
  mir-17-5p                                  MicroRNA 17                                                Act as oncogene or tumour suppressor gene depending on the cellular context
  mir-124-3p                                 MicroRNA 124                                               Abundant in the brain and involved in neurodegenerative disease
  ------------------------------------------ ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------
